Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714650 | 0.96 | PARP10 (0.41) | PARP10PARP15PARP2CNR2CHEK2 | |
| SCHEMBL30714624 | 0.88 | CNR2 (0.40) | PARP10PARP15PARP2SCN9ACNR2 | |
| SCHEMBL30714681 | 0.87 | CNR2 (0.43) | PARP10PARP15SCN9ACNR2ACACB | |
| SCHEMBL30714575 | 0.86 | GRM4 (0.39) | CNR2 | |
| SCHEMBL31539879 | 0.84 | PARP10 (0.49) | PARP10PARP15PARP2CHEK2ACACB | |
| SCHEMBL30714641 | 0.83 | CNR2 (0.40) | PARP10PARP15PARP2CNR2 | |
| SCHEMBL30714599 | 0.83 | CNR2 (0.40) | PARP10PARP15CNR2 | |
| SCHEMBL30714640 | 0.83 | CNR2 (0.36) | CNR2 | |
| SCHEMBL30714619 | 0.83 | KDM4E (0.43) | PARP10PARP15ACACBMTNR1A | |
| SCHEMBL30714578 | 0.82 | ACACB (0.43) | PARP10PARP15PARP2CNR2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | PARP10 1863/4885PARP15 1331/4885PARP2 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.